These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 25590272)
1. Pregnancy and contraceptive use among women participating in the FEM-PrEP trial. Callahan R; Nanda K; Kapiga S; Malahleha M; Mandala J; Ogada T; Van Damme L; Taylor D; J Acquir Immune Defic Syndr; 2015 Feb; 68(2):196-203. PubMed ID: 25590272 [TBL] [Abstract][Full Text] [Related]
2. FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. Corneli AL; Deese J; Wang M; Taylor D; Ahmed K; Agot K; Lombaard J; Manongi R; Kapiga S; Kashuba A; Van Damme L; J Acquir Immune Defic Syndr; 2014 Jul; 66(3):324-31. PubMed ID: 25157647 [TBL] [Abstract][Full Text] [Related]
3. Pregnancy incidence and outcomes among women receiving preexposure prophylaxis for HIV prevention: a randomized clinical trial. Mugo NR; Hong T; Celum C; Donnell D; Bukusi EA; John-Stewart G; Wangisi J; Were E; Heffron R; Matthews LT; Morrison S; Ngure K; Baeten JM; JAMA; 2014 Jul 23-30; 312(4):362-71. PubMed ID: 25038355 [TBL] [Abstract][Full Text] [Related]
4. Preexposure prophylaxis for HIV infection among African women. Van Damme L; Corneli A; Ahmed K; Agot K; Lombaard J; Kapiga S; Malahleha M; Owino F; Manongi R; Onyango J; Temu L; Monedi MC; Mak'Oketch P; Makanda M; Reblin I; Makatu SE; Saylor L; Kiernan H; Kirkendale S; Wong C; Grant R; Kashuba A; Nanda K; Mandala J; Fransen K; Deese J; Crucitti T; Mastro TD; Taylor D; N Engl J Med; 2012 Aug; 367(5):411-22. PubMed ID: 22784040 [TBL] [Abstract][Full Text] [Related]
5. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial. Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM; Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446 [TBL] [Abstract][Full Text] [Related]
7. Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. Corneli A; Wang M; Agot K; Ahmed K; Lombaard J; Van Damme L; J Acquir Immune Defic Syndr; 2014 Dec; 67(5):555-63. PubMed ID: 25393942 [TBL] [Abstract][Full Text] [Related]
8. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. Thigpen MC; Kebaabetswe PM; Paxton LA; Smith DK; Rose CE; Segolodi TM; Henderson FL; Pathak SR; Soud FA; Chillag KL; Mutanhaurwa R; Chirwa LI; Kasonde M; Abebe D; Buliva E; Gvetadze RJ; Johnson S; Sukalac T; Thomas VT; Hart C; Johnson JA; Malotte CK; Hendrix CW; Brooks JT; N Engl J Med; 2012 Aug; 367(5):423-34. PubMed ID: 22784038 [TBL] [Abstract][Full Text] [Related]
9. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. Donnell D; Baeten JM; Bumpus NN; Brantley J; Bangsberg DR; Haberer JE; Mujugira A; Mugo N; Ndase P; Hendrix C; Celum C J Acquir Immune Defic Syndr; 2014 Jul; 66(3):340-8. PubMed ID: 24784763 [TBL] [Abstract][Full Text] [Related]
10. Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. Mugwanya KK; Wyatt C; Celum C; Donnell D; Mugo NR; Tappero J; Kiarie J; Ronald A; Baeten JM; JAMA Intern Med; 2015 Feb; 175(2):246-54. PubMed ID: 25531343 [TBL] [Abstract][Full Text] [Related]
11. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis. Plosker GL Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256 [TBL] [Abstract][Full Text] [Related]
12. Tenofovir-based preexposure prophylaxis for HIV infection among African women. Marrazzo JM; Ramjee G; Richardson BA; Gomez K; Mgodi N; Nair G; Palanee T; Nakabiito C; van der Straten A; Noguchi L; Hendrix CW; Dai JY; Ganesh S; Mkhize B; Taljaard M; Parikh UM; Piper J; Mâsse B; Grossman C; Rooney J; Schwartz JL; Watts H; Marzinke MA; Hillier SL; McGowan IM; Chirenje ZM; N Engl J Med; 2015 Feb; 372(6):509-18. PubMed ID: 25651245 [TBL] [Abstract][Full Text] [Related]
13. Risk of drug resistance among persons acquiring HIV within a randomized clinical trial of single- or dual-agent preexposure prophylaxis. Lehman DA; Baeten JM; McCoy CO; Weis JF; Peterson D; Mbara G; Donnell D; Thomas KK; Hendrix CW; Marzinke MA; Frenkel L; Ndase P; Mugo NR; Celum C; Overbaugh J; Matsen FA; J Infect Dis; 2015 Apr; 211(8):1211-8. PubMed ID: 25587020 [TBL] [Abstract][Full Text] [Related]
14. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. Marcus JL; Glidden DV; Mayer KH; Liu AY; Buchbinder SP; Amico KR; McMahan V; Kallas EG; Montoya-Herrera O; Pilotto J; Grant RM PLoS One; 2013; 8(12):e81997. PubMed ID: 24367497 [TBL] [Abstract][Full Text] [Related]
15. Study design considerations for evaluating efficacy of systemic preexposure prophylaxis interventions. Donnell D; Hughes JP; Wang L; Chen YQ; Fleming TR J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S130-4. PubMed ID: 23764624 [TBL] [Abstract][Full Text] [Related]
16. Sino-implant (II)® continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya. Todd CS; Deese J; Wang M; Hubacher D; Steiner MJ; Otunga S; Van Damme L; Contraception; 2015 Mar; 91(3):248-52. PubMed ID: 25459097 [TBL] [Abstract][Full Text] [Related]
17. Continued attendance in a PrEP program despite low adherence and non-protective drug levels among adolescent girls and young women in Kenya: Results from a prospective cohort study. Tapsoba JD; Cover J; Obong'o C; Brady M; Cressey TR; Mori K; Okomo G; Kariithi E; Obanda R; Oluoch-Madiang D; Chen YQ; Drain P; Duerr A PLoS Med; 2022 Sep; 19(9):e1004097. PubMed ID: 36095005 [TBL] [Abstract][Full Text] [Related]
18. Tenofovir-based pre-exposure prophylaxis for HIV prevention: evolving evidence. Celum C; Baeten JM Curr Opin Infect Dis; 2012 Feb; 25(1):51-7. PubMed ID: 22156901 [TBL] [Abstract][Full Text] [Related]
19. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial. Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C; Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863 [TBL] [Abstract][Full Text] [Related]
20. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. Myers GM; Mayer KH AIDS Patient Care STDS; 2011 Feb; 25(2):63-71. PubMed ID: 21284497 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]